Vumerity generics — when can they launch?
Vumerity (DIROXIMEL FUMARATE) · Biogen · 3 active US patents · 0 expired
Where Vumerity sits in the generic timeline
Long-dated protection: earliest active US patent for Vumerity extends to 2033 (~7 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 2 patents
- Composition of Matter — 1 patent
FDA U-codes carved out by Vumerity patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-1384 | (no description) |
Sample patent estate
Showing 3 of 3 active US patents. View full estate on the Vumerity drug page →
-
This patent protects compounds of formula (I) and their pharmaceutical compositions.USPTO title: Prodrugs of fumarates and their use in treating various diseases
-
This patent protects compounds of formula (I) and their use in treating various diseases.USPTO title: Prodrugs of fumarates and their use in treating various diseases
-
This patent protects compounds of formula (I), which are prodrugs of fumarates, as described in the USPTO abstract.USPTO title: Prodrugs of fumarates and their use in treating various diseases
Sources
- FDA Orange Book — patents listed against Vumerity (NDA filed 2019)
- Vumerity drug profile — full patent estate, indications, clinical trials, pricing
- Biogen patent portfolio
- Patent cliff 2033 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Vumerity — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →